The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study.

ABSTRACT:

Background

We conducted a post-marketing surveillance study to evaluate the clinical tolerability and safety of atezolizumab in Japanese patients with non-small-cell lung cancer (NSCLC).

Methods

This prospective, observational post-marketing cohort study was conducted in NSCLC patients who received atezolizumab 1200 mg every 3 weeks at 770 facilities in Japan between April 18, 2018, and March 31, 2020 (study number UMIN000031978). Case report forms were completed, recording patient characteristics, treatment details, adverse events, adverse drug reactions (ADRs), their severity, onset and outcomes. Follow-up was for 12 months or until atezolizumab discontinuation.

Results

Overall, 2570 patients were included, median age was 69.0 years, and 69.9% were males. ADRs were

SUBMITTER: Ohe Y 

PROVIDER: S-EPMC9157296 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature